Dr Reddy's Labs announce the launch of Fenofibrate tablets USP

On Monday, Dr Reddy’s Laboratories announced the launch of Fenofibrate tablets USP in US market, a drug approved by United States Food & Drug Administration (USFDA).

The company’s Fenofibrate tablets USP are therapeutic equivalent generic version of Tricor (Fenofibrate) tablets and would be available in 54 mg dose in bottle count size of 90 and 160 mg dose in bottle count sizes of 90 and 500, the company said in a BSE filing.

According to IMS Health and Quintiles (IQVIA), Tricor brand and generic had US sales of approximately US$ 90 million MAT for the most-recent twelve months, ending in January 2020.

Dr Reddy's Laboratories Limited is a pharmaceutical company that manufactures bulk drugs and formulations including verapamil and cephalexin. The company also manufactures and exports molecules such as norfloxacin, ciprofloxacin and varieties of semi-synthetic penicillin. 

At 3 pm on Monday, the stock was trading at Rs 3,983, down by 0.48 per cent or Rs 19.25 per share. The 52-week high is recorded at Rs 4,095 and the 52-week low is Rs 2,352 on BSE.